Calif. September 14, 2021 – Qardio, Inc. announced today the launch of the first ever fully remote end-to-end RPM service to include cardiac arrhythmia analysis.
QardioDirect (Qardio’s all-inclusive service for RPM) now includes ambulatory Cardiac monitoring to help diagnose atrial fibrillation along with a large range of other arrhythmias. Multiple short duration recordings can identify symptomatic and asymptomatic periods of cardiac activity. Then as a more detailed analysis is needed, a full 24/48 hours Holter analysis can be prescribed with rapid turnaround and reporting. QardioDirect empowers clinicians to manage a full range of cardiovascular conditions in a fast, accurate and scalable solution.
Qardio’s Holter monitor, QardioCore, is the most patient-friendly Holter device available. No skin preparation is needed, there are no gels, no patches, and no wires, which provides optimum patient comfort. This ensures high patient compliance and high diagnostic yields, which results in better patient outcomes.
QardioDirect user George Fahnbulleh from Gold Canyon Internal Medicine, Arizona said “Thanks to Qardio, we’ve been able to catch at least three patients who had heart arrhythmias. We were then able to send them immediately to a cardiologist. The benefits of using QardioDirect are phenomenal.” George Fahnbulleh, Gold Canyon Internal Medicine, AZ
Qardio’s Co-Founder, Rosario Iannella says “Qardio’s history of innovation continues as we launch RPM & Holter analysis services in a single, unified workflow. QardioDirect is the only platform that enables practitioners to remotely identify changes in the patient baselines across multiple key vital signs and also diagnose a wide range of cardiac arrhythmias.”
QardioDirect with ECG is the future of RPM and Qardio are proud to be the pioneers of this exciting move in RPM history.